Hims & Hers Health announced on Tuesday it will bundle Wegovy with the telehealth platform’s membership through a new collaboration with drugmaker Novo Nordisk. The bundle will offer Novo ...

Hims & Hers (HIMS) stock popped more than 20% in trading early Tuesday after Novo Nordisk (NVO) announced a partnership with it and other telehealth platforms to offer patients access to the ...

Shelby Knowles / Bloomberg / Getty Images Hims & Hers Health shares surged Tuesday as the company announced a partnership with Danish drugmaker Novo Nordisk. Hims & Hers users will have access to ...

Hims & Hers Health Inc (NYSE:HIMS) stock is soaring today, up 22.6% at $34.92 at last glance, after news that the telehealth platform will offer Novo Nordisk's (NVO) popular weight-loss drug, Wegovy.

In a joint venture with Novo Nordisk, Hims & Hers will dispense all doses of Wegovy to Americans who buy eligible subscriptions, with plans starting at $599 a month. The offering will launch this ...

Hims & Hers Health (HIMS) stock declined about 2% yesterday. The fall came after the U.S. Food and Drug Administration (FDA) ...

Patients will be able to access the branded GLP-1 drug, at a discount, through the company's online pharmacy, NovoCare Pharmacy, directly through the telehealth platforms of Hims & Hers ...

Hims & Hers Health announced a partnership with Novo Nordisk to initially offer the FDA-approved Wegovy drug for weight loss while planning a long-term collaboration on future drugs. The news ...

Hims & Hers boasts excellent underlying performance, but the stock's current valuation remains uncomfortably high. Despite a 40% drop in stock price, shares are not yet a value, and selling put ...